Valuation : Ocular Therapeutix, Inc.

Market Cap 233.67Cr 201.07Cr 189.18Cr 172.82Cr 323.29Cr 22TCr 324.17Cr 2.24TCr 867.48Cr 11TCr 877.46Cr 858.32Cr 36TCr P/E 2026 *
-7.14x
P/E 2027 * -7.64x
Enterprise Value 195.87Cr 168.55Cr 158.58Cr 144.86Cr 270.99Cr 18TCr 271.73Cr 1.87TCr 727.15Cr 9.49TCr 735.52Cr 719.47Cr 31TCr EV / Sales 2026 *
37x
EV / Sales 2027 * 22.2x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Ocular Therapeutix, Inc.

1 week+2.70%
Current month+1.43%
1 month+25.18%
3 months+28.97%
6 months+3.00%
Current year-12.36%
1 week 10.13
Extreme 10.13
11.08
1 month 8.8
Extreme 8.8
11.74
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Sell

Chief Operating Officer

-1,099 0.0005%
25/08/26 Don

Chief Executive Officer

-1,00,184 0.0473%
24/08/26 Sell

Executive/Senior Manager

-3,035 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.70%-21.76%+171.43% 233.67Cr
-0.88%-2.15%+58.05%+105.91% 1,02400Cr
-1.15%+2.68%+54.25%+71.29% 66TCr
-1.44%+0.38%+20.65%+75.54% 45TCr
+0.14%-0.47%+30.20%+40.61% 35TCr
-1.33%+4.72%+24.62%+47.60% 30TCr
-1.15%+0.30%-0.69%+11.83% 25TCr
-1.55%+1.11%+54.15%+72.13% 24TCr
-0.88%+1.15%-14.60%-54.84% 21TCr
-0.15%+3.65%+31.24%+100.90% 19TCr
Average -0.84%+1.25%+23.61%+64.24% 36.81TCr
Weighted average by Cap. -0.96%+0.55%+37.59%+67.07%

Financials

2026 *2027 *
Net sales 5.29Cr 4.55Cr 4.29Cr 3.91Cr 7.32Cr 499.72Cr 7.34Cr 51Cr 20Cr 256.39Cr 20Cr 19Cr 825.97Cr 10Cr 8.82Cr 8.3Cr 7.58Cr 14Cr 967.55Cr 14Cr 98Cr 38Cr 496.42Cr 38Cr 38Cr 1.6TCr
Net income -33Cr -29Cr -27Cr -25Cr -46Cr -3.16TCr -46Cr -319.82Cr -124.11Cr -1.62TCr -125.53Cr -122.8Cr -5.22TCr -32Cr -28Cr -26Cr -24Cr -45Cr -3.06TCr -45Cr -310.36Cr -120.43Cr -1.57TCr -121.82Cr -119.16Cr -5.06TCr
Net Debt -38Cr -33Cr -31Cr -28Cr -52Cr -3.57TCr -52Cr -361.63Cr -140.33Cr -1.83TCr -141.94Cr -138.85Cr -5.9TCr -6.6Cr -5.68Cr -5.34Cr -4.88Cr -9.13Cr -623.14Cr -9.16Cr -63Cr -25Cr -319.72Cr -25Cr -24Cr -1.03TCr
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
04/26/04 $10.64 0.00% 13,06,871
03/26/03 $10.64 -2.39% 21,28,709
02/26/02 $10.90 +3.12% 20,68,790
01/26/01 $10.57 +0.76% 15,78,326
31/26/31 $10.49 +1.25% 15,20,523
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.64USD
Average target price
27.09USD
Spread / Average Target
+154.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock